Entering text into the input field will update the search result below

Relief Therapeutics agrees to acquire a novel dosage form of an already approved prescription drug for the treatment of PKU

Jul. 13, 2022 2:56 AM ETRelief Therapeutics Holding AG (RLFTF), RLFTYBy: Meghavi Singh, SA News Editor1 Comment
  • Relief Therapeutics Holding (OTCQB:RLFTF) said Wednesday that its wholly owned subsidiary, APR Applied Pharma Research SA in pact with Meta Healthcare, has acquired an additional therapeutic product for the management of patients with PKU for worldwide markets, with the exception of the United

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

sts66 profile picture
From the real PR:

"APR Applied Pharma Research SA (" APR "), has executed a definitive agreement with Meta Healthcare Ltd. (" Meta "), acquiring the worldwide rights, except for the United Kingdom (" UK "), for a novel dosage form of a prescription drug already approved by the FDA......As previously announced, under the terms of the agreement, Meta will provide the technology transfer package and Relief will conduct clinical studies, manufacturing, regulatory submission and commercialization in the U.S. and EU....We anticipate submission of an Investigational New Drug (IND) application at the earliest opportunity in order to file for FDA marketing approval in the first half of 2023, followed by a product launch in the U.S and Europe a year later."

WTF? Why do you need to file an IND and run clinical trials for a drug "already approved" by the FDA? They only had $49M as of 3/31/22 - they must not have paid much for this drug.

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.